Istituto Oncologico Veneto Irccs

This early-stage study tested adding a drug called regorafenib to the standard treatment for a fast-growing brain cancer called glioblastoma. The main goal was to find the highest dose of regorafenib that patients could safely take alongside their usual chemotherapy and radiation…

This trial tested whether adding a year of avelumab, an immunotherapy drug, after standard surgery and chemotherapy could help keep cancer from returning in patients with high-risk triple-negative breast cancer. It involved 474 patients who had already completed their main cancer…